|
|
| | Benzamide, 4-butoxy-N-[[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl]-3,5-dimethoxy-, hydrochloride (1:1) Basic information |
| Product Name: | Benzamide, 4-butoxy-N-[[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl]-3,5-dimethoxy-, hydrochloride (1:1) | | Synonyms: | 4-butoxy-N-[[4-(dimethylamino)oxan-4-yl]methyl]-3,5-dimethoxybenzamide;hydrochloride
4-butoxy-N-[[4-(dimethylamino)oxan-4-yl]methyl]-3,5-dimethoxybenzamide;Opiranserin hydrochloride;VVZ 149,analgesic,postoperative,VVZ-149,5-hydroxytryptamine Receptor,5-HT Receptor,anti-inflammatory,Opiranserin hydrochloride,Serotonin Receptor,Inhibitor,pain,GlyT,Opiranserin,non-opioid,inhibit,P2X Receptor,P2XRs,VVZ149,Glycine transporters;Benzamide, 4-butoxy-N-[[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl]-3,5-dimethoxy-, hydrochloride (1:1);Opiranserin hydrochloride, 10 mM in DMSO | | CAS: | 1440796-75-7 | | MF: | C21H34N2O5.ClH | | MW: | 430.97 | | EINECS: | | | Product Categories: | | | Mol File: | 1440796-75-7.mol | ![Benzamide, 4-butoxy-N-[[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl]-3,5-dimethoxy-, hydrochloride (1:1) Structure](CAS/20200401/GIF/1440796-75-7.gif) |
| | Benzamide, 4-butoxy-N-[[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl]-3,5-dimethoxy-, hydrochloride (1:1) Chemical Properties |
| storage temp. | Store at -20°C | | form | Solid | | color | White to off-white |
| | Benzamide, 4-butoxy-N-[[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl]-3,5-dimethoxy-, hydrochloride (1:1) Usage And Synthesis |
| Uses | Opiranserin (VVZ-149) hydrochloride, a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50s of 0.86 and 1.3 μM, respectively. Opiranserin hydrochloride shows antagonistic activity on rP2X3 (IC50=0.87 μM). Opiranserin hydrochloride is development as an injectable agent for the treatment of postoperative pain[1][2][3]. | | IC 50 | GlyT2: 0.86 μM (IC50); P2X3 Receptor; rP2X3: 0.87 μM (IC50); 5-HT2A Receptor: 1.3 μM (IC50) | | References | [1] Oh J, et al. Safety, Tolerability, and Pharmacokinetic Characteristics of a Novel Nonopioid Analgesic, VVZ-149 Injections in Healthy Volunteers: A First-in-Class, First-in-Human Study. J Clin Pharmacol. 2018 Jan;58(1):64-73. DOI:10.1002/jcph.973 [2] Nedeljkovic SS, et al. Randomised, double-blind, parallel group, placebo-controlled study to evaluate the analgesic efficacy and safety of VVZ-149 injections for postoperative pain following laparoscopic colorectal surgery. BMJ Open. 2017 Feb 17;7(2):e011035. DOI:10.1136/bmjopen-2016-011035 [3] Pang MH, et al. A series of case studies: practical methodology for identifying antinociceptive multi-target drugs. Drug Discov Today. 2012 May;17(9-10):425-34. DOI:10.1016/j.drudis.2012.01.003 |
| | Benzamide, 4-butoxy-N-[[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl]-3,5-dimethoxy-, hydrochloride (1:1) Preparation Products And Raw materials |
|